UNDP, working in partnership with the Global Fund and national partners, has provided 258,000 counselling and testing encounters for HIV and antiretroviral treatment for 10,000 people.
Key results - HIV
UNDP has been the PR of Global Fund grants in Iran since 2005 for HIV, 2008 for TB and since 2011 for malaria. For HIV/AIDS, Iran is the only country in the region that has committed itself to reach the global target of 90-90-90 to help end the AIDS epidemic by 2020 and in line with these ambitious targets, the 4th National Strategic Plan and the Global Fund (GF) HIV grants have been developed and are being implemented.
The key population of the HIV GF project are people who inject drugs, HIV vulnerable women and prisoners who are receiving HIV diagnostic test and other related prevention programmes, as well as treatment, care and support for people living with HIV and their families. There are various settings in which the project is being carried out, including Voluntary Counselling and Testing Centres, Drop-In-Centres, Out-reach teams, Mobile Clinics and Positive Clubs. The project has also supported the national counterpart to improve resilient and sustainable systems for health. Iran was eligible to receive a continuation grant for April 2018-March 2021 which is aligned with priorities in the 4th NSP with the goal of limiting prevalence rates among key populations (13% for injecting drug users and 5% for men and women engaged in risky sexual behaviour). There is also a target to reduce HIV- related mortality by 20% over the same period.
572,000 counselling and testing encounters for HIV
10,000 people currently on ART
Source: UNDP (2018)
Retention on ART 12 months after starting treatment
81% prevention of transmission of HIV from mother to child
Source: UNAIDS (2018)
90,000 key populations and vulnerable people reached with HIV prevention programmes
Source: UNDP (2018)
Key results - malaria & TB
The aim of the malaria grant (no longer funded by the Global Fund) was elimination of P. Falciparum malaria by 2016 and all cases of malaria including P. Vivax by 2025. The TB programme (also no longer funded by the Global Fund) supported the priority gaps in the National Tuberculosis (TB) Control Programme, dramatically reducing the burden of TB in poor and vulnerable populations in line with the SDGs and the Stop TB Partnership targets. The programme included measures to enhance treatment practices, addressing issues related to TB/HIV combination and drug resistant, empowering TB affected people/communities, and enhancing TB control systems and infrastructure.
Case detection rate for TB. Above the global target (70%)